June 18, 2018
Rose
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.
from MobiHealthNews https://ift.tt/2JY1LcV
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment